Aileron Therapeutics Commences Enrollment in a Phase 2a

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
36
Aileron Therapeutics Commences Enrollment in a Phase 2a Expansion Cohort for ALRN-6924 in Combination with Pfizer’s IBRANCE® (palbociclib) in Patients with MDM2-Amplified Cancers

WATERTOWN, Mass., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN ), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer and other diseases, today announced that the first patient has been enrolled in a Phase 2a expansion cohort intended to assess preliminary activity and safety of ALRN-6924 in combination with Pfizer’s palbociclib, also known as IBRANCE®, in cancer patients with MDM2-amplified solid tumors.

“We are excited to launch this Phase 2a expansion cohort, expanding on our ALRN-6924 clinical trial combination program,” said Vojo Vukovic, MD, PhD, and Chief Medical Officer of Aileron. “ALRN-6924 and palbociclib address the MDM2 (p53) and CDK4 (Rb) pathways, which have interdependent roles in cancer biology, and preclinical results recently presented by Aileron show synergistic activity for ALRN-6924 and palbociclib in cancer cells and animal models 1 .  Furthermore, the MDM2 and CDK4 genes are co-amplified in many cancers.  We are using this biomarker-driven approach to select cancer patients with tumors exhibiting this genetic profile.  We are hopeful that a dual MDM2 and CDK4 inhibition strategy will benefit these patients.”

About the Phase 2a MDM2-amplified Expansion Cohort This Phase 2a expansion cohort is intended to assess the preliminary activity and safety of ALRN-6924 in combination with palbociclib. The trial is expected to enroll up to 25 MDM2-amplified cancer patients with advanced solid tumors that test positive for the presence of wild-type p53. The objectives of the trial include determining the overall response rate and other parameters of efficacy, as well as evaluating the safety and tolerability of the combination.  Aileron expects to present preliminary data in the second half of 2019 at a medical conference.

ALRN-6924 is a first-in-class, stabilized cell-permeating peptide that mimics the p53 tumor suppressor protein to disrupt the interaction with both p53-inhibitors, MDMX and MDM2.  For p53 wild-type tumors, ALRN-6924 can restore p53-dependent tumor suppression.  Palbociclib is an oral inhibitor of cell cycle check-point regulators CDK4/6.  The MDM2 and CDK4 genes are located on chromosome 12 in close proximity to each other, with CDK4 very frequently co-amplified in patients with MDM2-amplified cancers who will be enrolled in this trial.  This co-amplification provides the mechanistic rationale and suggests a potential patient benefit from combining the MDM2/MDMX-inhibitor, ALRN-6924, with the CDK4/6-inhibitor, palbociclib 2 .

1. 2018 San Antonio Breast Cancer Symposium abstract #1129, “The Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, and the CDK4/6 Inhibitors Palbociclib, Ribociclib, or Abemaciclib Synergistically Enhance Each Other’s in vitro and in vivo Anticancer Activity"

2. Laroche-Clary et al. Journal of Hematology & Oncology (2017) 10:123 DOI 10.1186/s13045-017-0482-3

About ALRN-6924 ALRN-6924 is currently being evaluated in multiple clinical trials for the treatment of solid and hematological cancers, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). For information about Aileron’s clinical trials, please visit www.clinicaltrials.gov .

About Aileron Aileron is a clinical-stage biopharmaceutical company advancing a proprietary platform of cell-permeating alpha-helical peptides that address the most important intracellular targets in oncology and other therapeutic areas. The stabilized helical structure of our peptides allows the design of cell-permeating therapeutic agents with large molecular surfaces for optimal target binding properties, resulting in unique drugs like ALRN-6924. Our current focus is to improve the standard of care for patients with solid tumors and hematological malignancies by developing safe and effective therapies that leverage our proprietary peptide platform. For more information, visit www.aileronrx.com , and for more information about our clinical trials please visit  www.clinicaltrials.gov .

Forward-Looking Statements Statements in this press release about Aileron's future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about the Company’s strategy and clinical development plans. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether Aileron’s cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; whether results obtained in preclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether Aileron’s product candidates will advance through the clinical trial process on a timely basis, or at all; whether the results of such trials will warrant submission for approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether Aileron's product candidates will receive approval from regulatory agencies on a timely basis or at all; whether, if product candidates obtain approval, they will be successfully distributed and marketed; whether the Company will be able to enter into additional collaborations;  and other factors discussed in the "Risk Factors" section of Aileron's quarterly report on Form 10-Q for the period ended September 30, 2018, filed on November 7, 2018, and risks described in other filings that Aileron may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Aileron specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.

Investors: Aileron Therapeutics Don Dougherty, CFO 617-995-0900 Hans C. Vitzthum LifeSci Advisors, LLC. 617-535-7743

Scroll down for more posts ▼

Top 10 Most Recent News Articles

EUBG Faces Tough Third Quarter Amid Challenges

Updated Category News Views 173

What's Happening with EUBG? Entrepreneur Universe Bright Group, better known in the markets as EUBG, is navigating some choppy waters if their recent financial numbers are anything to go by. You'd think companies boasting a digital-focused strategy would be printing money in today's tech-driven world, but EUBG's third quarter of 2026 has a different story to tell. The...

Continue Reading
Waterfall Backs $48M Loan for Disney-area Hotel Upgrade

Updated Category News Views 259

A $48 Million Shot in the Arm for Portofino Inn Old-school Anaheim just got a real estate shake-up. Waterfall Asset Management's decision to lend a hefty $48 million to Dynamic City Capital (DCC) is more than just a financial move—it's a bet on tourism's bedrock, Disneyland. They're sinking this cash into the Portofino Inn & Suites, located a stone's throw from the...

Continue Reading
Endava's Audit Scandal: Investors Face Crucial Decision

Updated Category News Views 142

Endava's Unexpected Crisis: What's Happening? It's the kind of mess no investor wants to wake up to: on October 28, 2026, Endava plc (NYSE: DAVA) laid out a smorgasbord of screw-ups that have left the market reeling. The company's last few days were a whirlwind, featuring the CFO's abrupt exit and the CEO swap. This shake-up didn't happen in isolation—the announcement...

Continue Reading
Nasdaq Tumbles: AI Hardware Pulls Markets Down

Updated Category News Views 74

Wall Street's Slide Fueled by AI Nerves The markets got a real jolt on Monday, sending Nasdaq down 2.5% thanks to a sharp dip in AI hardware stocks. Tech tickers tied to artificial intelligence were at the core of a sell-off, knocking the S&P 500 down 1.92% alongside it. Investors are on edge, and it’s not just the weather—it's a real shake-up driven by policy moves...

Continue Reading
Scientific Games Joins NCPG’s 2026 Campaign Again

Updated Category News Views 207

Scientific Games Backs Responsible Gaming Again It's another year, and here's Scientific Games once more, guns blazing for a cause that's needed more than a few times over—responsible gambling. Those folks got their hearts in the right place, joining the National Council on Problem Gambling's 2026 Gift Responsibly campaign. Ninth time running, no less! It's like...

Continue Reading
SKE Capitalizes on Halloween Events in London

Updated Category News Views 70

SKE's Bold Step into London's Halloween Vibe Hah! Who would've thought that vaping and Halloween could be a match made in heaven? This year, SKE threw its hat into the ring and wrestled for attention in London’s bustling Halloween music scene. Imagine an entire warehouse pulsing not just with beat-heavy electronic music, but the energy of vaping enthusiasts courtesy of...

Continue Reading
Mall of America Strives for World Record This Black Friday

Updated Category News Views 228

History in the Making at Mall of America Yeah, it seems these folks are not just about shopping anymore. The Mall of America is aiming to set the bar high this Black Friday, eyeing a GUINNESS WORLD RECORDS title for the most people holding up the same shopping bag all at once. Imagine a thousand people, synchronized like a flash mob—only with shopping bags instead of...

Continue Reading
Kos & FORTH Partner to Spark Greek Biotech Growth

Updated Category News Views 65

New Frontiers: Greece on the Biotech Map Partnerships in biotech aren't tossed out willy-nilly; they're crafted for precision much like a sculptor shaping marble. Kos Biotechnology Partners and the Foundation for Research and Technology-Hellas (FORTH) are doing exactly that, teaming up to birth a biotechnology incubator on the FORTH campus in Heraklion, Crete. Now tell...

Continue Reading
Exploring Creation: A Fresh Look at Genesis

Updated Category News Views 67

Opening Up Genesis in a New Light Hey, if you’re like most folks, you’ve probably heard Genesis framed as the battleground for science versus religion debates, right? Enter into this mix a fresh take with Robert E. Franzen’s new book, The Narration of Creation. This book asks you to overlook those grand philosophical fights and instead focus on the narrative itself....

Continue Reading
A&G Management's Bold New Era with WPM Partnership

Updated Category News Views 122

Shaking Up Baltimore's Real Estate Scene Swapping up management partners can be a dicey game, but A&G Management seems to be pulling it off without a hitch. As of January 4, 2027, WPM Real Estate Management will take over the reins for more than 3,000 apartment homes scattered across Anne Arundel, Howard, and Baltimore counties. A new set of hands is stepping in for...

Continue Reading

Top 5 Most Recently Viewed Articles

Nokia Enhances Open Networking with SONiC Premier Membership

Updated Category News Views 221

Nokia Joins the SONiC Foundation as a Premier Member Nokia has made significant strides in open networking by becoming a Premier member of the SONiC Foundation. This membership highlights Nokia's ongoing commitment to fostering innovation in AI-scale networking, enabling cloud-based infrastructures. Strengthening SONiC's Ecosystem The SONiC Foundation has been pivotal in...

Continue Reading
Ember Collaborates with Zion Shores for Exciting Housing Options

Updated Category News Views 224

Exciting New Partnership Announcement In a remarkable development for the luxury vacation home market, Ember has partnered with Zion Shores™ to introduce innovative co-ownership and whole home ownership options. As a leader in high-end vacation home management, Ember is poised to reshape the hospitality experience in this stunning surf community. About the Surf...

Continue Reading
WM Technology Investors Take Action Amid SEC Charges and Lawsuit

Updated Category News Views 64

Important Update on WM Technology, Inc. (NASDAQ: MAPS) In recent weeks, WM Technology, Inc., a pivotal player in the online cannabis marketplace, has come under heavy scrutiny following the filing of a class action lawsuit. This legal action arises on behalf of investors who bought or acquired the company’s securities during a defined period of heightened concern....

Continue Reading
DXP Enterprises Plans Third Quarter Earnings Call Details

Updated Category News Views 133

DXP Enterprises Announces Upcoming Earnings Release In an essential update for investors and stakeholders, DXP Enterprises, Inc. (NASDAQ: DXPE), a prominent distributor of business-to-business products and services, is scheduled to release its financial results for the third quarter soon. The earnings announcement will be unveiled after the stock market closes, with all...

Continue Reading
KONKA Unveils Groundbreaking 110-Inch 8K TV at Fair

Updated Category News Views 254

KONKA Introduces Revolutionary 110-Inch 8K Television at Canton Fair KONKA Group Co., Ltd. is making waves at the 136th Canton Fair, revealing its latest technological innovations and products that demonstrate the company's commitment to excellence in television and home appliances. Among the numerous products on display, the KONKA 110A8 Ultra Mini AI-LED TV stands out as...

Continue Reading